AMGN - Amgen Inc.
170.00 +0.31 (0.18%)
After hours: 5:25PM EDT
| Previous close | 168.39 |
| Open | 169.77 |
| Bid | 169.61 x 800 |
| Ask | 169.68 x 800 |
| Day's range | 168.68 - 170.02 |
| 52-week range | 166.30 - 210.19 |
| Volume | 1,922,705 |
| Avg. volume | 2,880,670 |
| Market cap | 103.5B |
| Beta (3Y monthly) | 0.90 |
| PE ratio (TTM) | 13.53 |
| EPS (TTM) | 12.54 |
| Earnings date | 24 Jul 2019 - 29 Jul 2019 |
| Forward dividend & yield | 5.80 (3.23%) |
| Ex-dividend date | 2019-05-16 |
| 1y target est | 206.10 |
- Zacks•yesterday
Ligand Grants Preclinical Candidate Rights to UK-based Firm
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
- Motley Fool•4 days ago
Who Had the Better Quarter: Gilead Sciences or Amgen?
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
- Motley Fool•5 days ago
Here's Why Mirati Therapeutics Is Surging Today
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
- Barrons.com•6 days ago
Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
- Motley Fool•6 days ago
3 Stocks With Big News Coming at ASCO 2019
These cancer drug developers could report market-moving news soon.
- Zacks•6 days ago
AbbVie Settles Humira Litigation With Boehringer Ingelheim
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
- Zacks•7 days ago
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
- Zacks•7 days ago
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
- Simply Wall St.•7 days ago
Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•8 days ago
Top Stock Reports for Amgen, Altria & Booking Holdings
Top Stock Reports for Amgen, Altria & Booking Holdings
- Zacks•12 days ago
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
- Zacks•14 days ago
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
- Zacks•14 days ago
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
- Motley Fool•15 days ago
3 Top Biotech Stocks to Buy in May
These three biotech stocks could be prime comeback candidates.
- Zacks•18 days ago
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
Ligand (LGND) first-quarter earnings and sales decrease year over year.
- Zacks•19 days ago
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
- Zacks•19 days ago
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
- Zacks•20 days ago
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
Key highlights of the past week are earnings releases by most leading biotech entities.
- Zacks•20 days ago
Can Allergan (AGN) Beat Earnings Estimates Again in Q1?
Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
- Zacks•20 days ago
Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
- Investing.com•21 days ago
Amgen Falls 4%
Investing.com - Amgen (NASDAQ:AMGN) fell by 3.52% to trade at $173.00 by 09:47 (13:47 GMT) on Wednesday on the NASDAQ exchange.
Motley Fool•21 days agoAmgen Inc (AMGN) Q1 2019 Earnings Call Transcript
AMGN earnings call for the period ending March 31, 2019.
- Motley Fool•21 days ago
Amgen Reports an Unusual Slide Backward
The first three months of the year weren't nearly as positive as investors had hoped for.
- Barrons.com•21 days ago
Fending Off Rivals, Amgen Posts Better Than Expected Sales
The drugmaker managed to keep sales steady as it seeks to protect its turf against biosimilar competitors for two of its key cancer drugs. It’s still waiting for new products to kick in more strongly.
- MarketWatch•21 days ago
Amgen stock rises on company's earnings beat, Neulasta sales fall 12%
Shares of Amgen Inc. rose more than 1% in the extended session Tuesday after the drug company reported adjusted first-quarter profit and sales above expectations. Amgen said it earned $2 billion, or $3.18 a share, in the quarter, compared with $2.3 billion, or $3.25 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $3.56 a share, compared with $3.47 a share a year ago. Revenue was flat at $5.6 billion. Analysts polled by FactSet had expected adjusted earnings of $3.48 a share on sales of $5.5 billion. Sales of its drug Neulasta fell 12% mostly because of lower net selling price and inventory changes, Amgen said. Enbrel drug sales rose 4%, which the company pinned on "favorable impacts" from changes in accounting sales estimates. Amgen shares ended the regular trading day down 1%.
